Association of Serum Asprosin With Metabolic Syndrome and Cardiometabolic Risk in Patients With Rheumatoid Arthritis
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 75
- 主要终点
- Serum Asprosin Level
研究概览
简要总结
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with a significantly increased risk of cardiovascular disease and metabolic syndrome (MetS). Asprosin is a recently identified adipokine involved in glucose regulation, insulin resistance, and systemic inflammation, but its role in the cardiometabolic complications of RA remains incompletely understood.
The purpose of this case-control study is to evaluate and compare serum Asprosin levels among RA patients with metabolic syndrome, RA patients without metabolic syndrome, and healthy control individuals. The study will also assess the association between serum Asprosin concentrations, RA disease activity (DAS28-ESR), and various cardiometabolic risk indices (including TyG index, Atherogenic Index of Plasma, and Castelli risk indices).
Participants will undergo a comprehensive clinical assessment, disease activity scoring, physical function evaluation using the Health Assessment Questionnaire (HAQ), and laboratory investigations including fasting blood tests and serum Asprosin measurement via ELISA. Findings from this study may help clarify the pathophysiological role of Asprosin in RA and improve cardiometabolic risk stratification in affected patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients aged 18 years or older.
- •Diagnosis of rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria.
- •Ability and willingness to provide written informed consent.
- •Healthy controls: Age- and sex-matched individuals without rheumatoid arthritis or systemic inflammatory diseases.
排除标准
- •Presence of other autoimmune diseases or overlap syndromes.
- •Active acute or chronic infectious diseases.
- •Pregnancy or lactation.
- •Current malignancy or previous history of malignancy.
- •Severe hepatic or renal impairment.
- •Receipt of medications primarily prescribed for weight reduction or agents known to markedly alter lipid or glucose metabolism, other than standard rheumatoid arthritis therapy.
研究组 & 干预措施
Rheumatoid Arthritis with Metabolic Syndrome
Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria who also meet the NCEP ATP III criteria for metabolic syndrome (presence of 3 or more metabolic components). Serum Asprosin levels and cardiometabolic risk indices will be evaluated.
Rheumatoid Arthritis without Metabolic Syndrome
Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria who do not meet the NCEP ATP III diagnostic criteria for metabolic syndrome. Serum Asprosin levels and cardiometabolic risk indices will be evaluated.
Healthy Controls
Age- and sex-matched healthy control individuals without rheumatoid arthritis, metabolic syndrome, or systemic inflammatory conditions, recruited for comparative assessment of baseline serum Asprosin levels.
结局指标
主要结局
Serum Asprosin Level
时间窗: Baseline
Serum asprosin concentration (measured in ng/mL) assessed via a commercial enzyme-linked immunosorbent assay (ELISA) kit to compare rheumatoid arthritis patients with metabolic syndrome versus rheumatoid arthritis patients without metabolic syndrome.
次要结局
未报告次要终点
研究者
Viola Rafaat Shafik Tadros
Resident of Rheumatology, Rehabilitation and Physical medicine
Assiut University